Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
TEL AVIV, ISRAEL, Jan. 03, 2018 -- InspireMD, Inc. (NYSE AMER: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that it will host a conference call on Wednesday, January 10th at 10:00 a.m. Eastern Time to discuss recent developments, preliminary unaudited fourth quarter 2017 sales results, and proposals under consideration for the upcoming shareholder meeting. A link to the Company’s definitive proxy statement is available at: https://www.sec.gov/Archives/edgar/data/1433607/000149315217015034/def14a.htm.
The conference call will be available via telephone by dialing toll free 877-407-0782 for U.S. callers or +1 201-689-8567 for international callers, or on the Company’s Investor Relations section of the website: http://www.inspiremd.com/en/investors/investor-relations/.
A webcast will also be archived on the Company’s website and a telephone replay of the call will be available approximately one hour following the call, through midnight January 24, 2018, and can be accessed by dialing 877-481-4010 for U.S. callers or +1 919-882-2331 for international callers and entering conference ID: 23561.
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet™ technology to make its products the industry standard for embolic protection and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events.
InspireMD intends to pursue applications of this MicroNet technology in coronary, carotid (CGuard™), neurovascular, and peripheral artery procedures. InspireMD's common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants are quoted on the NYSE American under the ticker symbol NSPR.WS.
Investor Contacts: InspireMD, Inc. Craig Shore Chief Financial Officer Phone: 1-888-776-6804 Email: [email protected] Crescendo Communications, LLC David Waldman Phone: (212) 671-1021 Email: [email protected]
